Inify Laboratories have decided to establish its operation to the United Kingdom and expand diagnostics to the gastrointestinal field. One of the major challenges in the UK is long and unpredictable response times and varying quality in prostate cancer care. The market is six times larger than Sweden´s in terms of patient volume, with approximately 120,000 patients annually who require diagnosis.
“The national health care system NHS in the UK has a high focus on pathways for patients that are going through cancer investigations, and here is exactly where we provide unique value” says Inify´s CEO Fredrik Palm. More details about the geographical expansion and the gastrointestinal diagnostics are discussed in the panel talk led by Ole Eikeland with CEO Fredrik Palm.
Link to the panel talk is available here.